Search

Mircera

Mircera

methoxy polyethylene glycol-epoetin beta

Manufacturer:

Roche

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Methoxy polyethylene glycol-epoetin β
Indications/Uses
Anaemia associated w/ CKD in dialysis & non-dialysis patients.
Click to view Mircera detailed prescribing information
Dosage/Direction for Use
Erythropoiesis stimulating agent (ESA)-naive patient not on dialysis 1.2 mcg/kg SC inj once mthly. Alternatively, 0.6 mcg/kg IV or SC inj once every 2 wk. ESA-naive patient on dialysis 0.6 mcg/kg IV or SC inj once every 2 wk, may be increased by 25-50% of previous dose if rate of rise in Hb <1 g/dL over a mth. ESA-treated patient Start Mircera IV or SC inj once mthly or once every 2 wk.
Click to view Mircera detailed prescribing information
Overdosage
View Mircera overdosage for action to be taken in the event of an overdose.
Contraindications
Hypersensitivity. Uncontrolled HTN.
Click to view Mircera detailed prescribing information
Special Precautions
Discontinue use if pure red cell aplasia is diagnosed; severe cutaneous skin reaction eg, SJS or TEN develops. Fe deficiency & inflammatory disorders; chronic blood loss, bone marrow fibrosis, severe Al overload, folic acid or vit B12 deficiencies & hemolysis. Patients w/ hemoglobinopathies, seizures or platelet level >500 x 109/L. May lead to excessive increase in Hb for non-anaemic persons. Evaluate Fe status & adequately control BP prior to & during treatment. Monitor closely for skin reactions. Not to be switched to Mircera if Ab to erythropoietin is suspected or confirmed. Pregnancy & lactation. Ped <18 yr.
Click to view Mircera detailed prescribing information
Caution For Usage
For caution against possible variation of physical aspect of medicine... Click to view Mircera detailed prescribing information
Storage
View Mircera storage conditions for details to ensure optimal shelf-life.
Description
View Mircera description for details of the chemical structure and excipients (inactive components).
Action
View Mircera mechanism of action for pharmacodynamics and pharmacokinetics details.
MIMS Class
Haematopoietic Agents
ATC Classification
B03XA03 - methoxy polyethylene glycol-epoetin beta ; Belongs to the class of other antianemic preparations. Used in the treatment of anemia.
Patient Counseling Information
View Mircera patient counselling information
Presentation/Packing
Form
Mircera inj (pre-filled syringe) 100 mcg/0.3 mL
Packing/Price
1's
Form
Mircera inj (pre-filled syringe) 120 mcg/0.3 mL
Packing/Price
1's
Form
Mircera inj (pre-filled syringe) 150 mcg/0.3 mL
Packing/Price
1's
Form
Mircera inj (pre-filled syringe) 200 mcg/0.3 mL
Packing/Price
1's
Form
Mircera inj (pre-filled syringe) 50 mcg/0.3 mL
Packing/Price
1's
Form
Mircera inj (pre-filled syringe) 75 mcg/0.3 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in